Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Terminated 2Recruiting 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 1Breast 1

Conditions

Cardiotoxicity 2Renal Insufficiency, Chronic 1Kidney Neoplasms 1Heart Failure 1Carcinoma, Renal Cell 1Breast Neoplasms 1

Interventions

pembrolizumab 603Cyclophosphamide 545Magnetic Resonance Spectroscopy 527Radiotherapy 513Specimen Handling 505Nivolumab 411Cisplatin 381Carboplatin 369Biopsy 305Blood Specimen Collection 304Radiosurgery 290Paclitaxel 281Gemcitabine 271Surveys and Questionnaires 269Standard of Care 267fludarabine 263Drug Therapy 263Dexamethasone 263Bevacizumab 252venetoclax 251Oxaliplatin 209Capecitabine 199Rituximab 198Radiation 191Ipilimumab 188Fluorouracil 188durvalumab 185Doxorubicin 178Etoposide 177atezolizumab 172

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × empagliflozin × 1 year × Clear all
NCT06844669 2026-05-13

HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy

Washington University School of Medicine

Phase 2 Terminated
7 enrolled
Breast

Breast Neoplasms, Heart Failure, Cardiotoxicity

NCT06818305 2025-12-11

EmFin-Nx

Jinling Hospital, China

Phase 2 Terminated
10 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms, Renal Insufficiency, Chronic

NCT05271162 2025-11-21

EMPACT

Maria Sklodowska-Curie National Research Institute of Oncology

Phase 3 Recruiting
220 enrolled

Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡